Q3 2024 ReportResults in line for Q3 2024 with sales momentum increasing throughout the period and into Q4GIG Software Plc ...
Moderna (MRNA) is up more than +3% after reporting Q3 Covid-19 vaccine revenue of $1.8 billion, which is stronger than the consensus of $1.2 billion. Lyft (LYFT) is up more than +29% after reporting ...
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
Coupang (CPNG) fell -10% after reporting Q3 retail net sales of $6.14 billion ... Insulet Corp (PODD), Kenvue Inc (KVUE), Mettler-Toledo International Inc (MTD), Moderna Inc (MRNA), Molson Coors ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
Moderna ( (MRNA) ) has released its Q3 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a ...
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
Benzinga (Video) on MSN7d
Moderna Posts Unexpected Q3 Profit, Driven by Cost Cuts and Strong Covid Vaccine SalesModerna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.
Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback